公开(公告)号：US20080255173A1

公开(公告)日：2008-10-16

申请号：US11791922

申请日：2005-11-02

Applicant: Claude Lardy ,  Marc Lecomte ,  Catherine Vidal ,  Thierry Convard ,  Stephane Yvon ,  Marie Noelle Denuault ,  Denis Descours

Inventor： Claude Lardy ,  Marc Lecomte ,  Catherine Vidal ,  Thierry Convard ,  Stephane Yvon ,  Marie Noelle Denuault ,  Denis Descours

IPC: A61K31/44 ,  C07C57/38 ,  C07D213/55 ,  A61P27/02 ,  A61K31/192

CPC classification number: A61K31/192 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K31/53 ,  C07C57/38 ,  C07C57/58 ,  C07C59/64

Abstract: The invention relates to compounds of the general formula (I), and to their use as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy.

Abstract translation: 本发明涉及通式（I）的化合物及其作为半胱天冬酶-10抑制剂的用途，特别是用于治疗糖尿病性视网膜病变。

公开(公告)号：US20060111445A1

公开(公告)日：2006-05-25

申请号：US10542028

申请日：2003-12-16

Applicant: Nathalie Adje ,  Michel Brunet ,  Didier Roche ,  Jean-Jacques Zeiller ,  Stephane Yvon ,  Valerie Guyard-Dangremont ,  Francis Contard ,  Daniel Guerrier ,  Gerard Ferrand

Inventor： Nathalie Adje ,  Michel Brunet ,  Didier Roche ,  Jean-Jacques Zeiller ,  Stephane Yvon ,  Valerie Guyard-Dangremont ,  Francis Contard ,  Daniel Guerrier ,  Gerard Ferrand

IPC: A61K31/195 ,  A61K31/192 ,  C07C251/44 ,  C07C321/24

CPC classification number: C07C323/56 ,  C07C45/46 ,  C07C45/673 ,  C07C45/68 ,  C07C49/747 ,  C07C49/755 ,  C07C59/72 ,  C07C59/90 ,  C07C65/40 ,  C07C67/30 ,  C07C67/31 ,  C07C69/712 ,  C07C69/736 ,  C07C69/76 ,  C07C205/45 ,  C07C211/60 ,  C07C229/18 ,  C07C233/33 ,  C07C251/44 ,  C07C255/40 ,  C07C309/65 ,  C07C317/44 ,  C07C323/22 ,  C07C323/52 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/42 ,  C07C47/575

Abstract: The present invention relates to a compound of the formula ((I): in which: n is an integer chosen from 1, 2 and 3; Y represents O; N—OR9, in which R9 represents H or a saturated hydrocarbon-based aliphatic group; CR10R11, in which R10 and R11, which may be identical or different, represent H or a saturated hydrocarbon-based aliphatic group; R1 and R2, which may be identical or different, represent H or a saturated aliphatic hydrocarbon-based chain; or alternatively R1 and R2 together form an optionally substituted saturated aliphatic hydrocarbon-based chain; the radicals R3 and R4, which may be identical or different, take any of the is meanings given above for R1 and R2, or alternatively R1 and the group R4 borne by the carbon alpha to CR1R2 represent nothing and a double bond links the CR1R2 carbon to the alpha CR3R4 carbon; or alternatively one of the radicals R1 and R2 forms with one of the radicals R3 and R4 an optionally substituted saturated or unsaturated aliphatic hydrocarbon-based chain; one of the radicals R5 and R6 represents W, and the other represents Z which is chosen from a saturated or unsaturated aliphatic hydrocarbon-based radical; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic or heterocyclic radical; a radical -alk-Cy, in which alk represents an alkylene chain and Cy represents an optionally substituted saturated, unsaturated and/or aromatic heterocyclic or carbocyclic radical; W represents —XL-CO2R7; —X-L-Tet, in which X and L are as defined below and Tet represents optionally substituted tetrazole; in which L represents a saturated or unsaturated aliphatic hydrocarbon-based chain, which is optionally substituted and/or optionally interrupted by optionally substituted arylene; X represents O; NR8, in which R8 represents H; a saturated aliphatic hydrocarbon-based group; a group —CO—R′ or —SO2—R′, in which R′ takes any of the meanings given below for R7 with the exception of H; or R8 represents an optionally substituted aromatic carbocyclic group; or X represent S(O)m, in which m is chosen from 0, 1 and 2; R7 represents H; a saturated or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic group; an optionally substituted, saturated, unsaturated and/or aromatic heterocyclic group; and the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, and also mixtures thereof in all proportions, which can be used in the treatment of dyslipidaemia, atherosclerosis and diabetes.

公开(公告)号：US20080114034A1

公开(公告)日：2008-05-15

申请号：US11813922

申请日：2005-12-17

Applicant: Nathalie Adje ,  Didier Roche ,  Stephane Yvon

Inventor： Nathalie Adje ,  Didier Roche ,  Stephane Yvon

IPC: A61K31/4439 ,  C07D209/18 ,  A61K31/404 ,  A61P3/10 ,  A61P9/10 ,  C07D401/02

CPC classification number: C07D401/04 ,  C07D209/42 ,  C07D405/04

Abstract: Compounds of the formula (1): in which A, R1, R2 and R3 are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.

Abstract translation: 式（1）的化合物：其中A，R 1，R 2和R 3如在说明书中所定义，方法 用于制备这些化合物，其用于治疗血脂异常，动脉粥样硬化和糖尿病的用途，以及包含它们的药物组合物。

公开(公告)号：US20080161308A1

公开(公告)日：2008-07-03

申请号：US11813933

申请日：2005-12-22

Applicant: Catherine Vidal ,  Nathalie Adje ,  Stephane Yvon ,  Jean Jacques Zeiller

Inventor： Catherine Vidal ,  Nathalie Adje ,  Stephane Yvon ,  Jean Jacques Zeiller

IPC: A61K31/5377 ,  A61P9/10 ,  A61K31/421 ,  A61K31/085 ,  C07D265/30 ,  C07C39/04 ,  C07C63/06 ,  C07D263/30 ,  A61K31/192 ,  A61P3/10

CPC classification number: C07D295/205 ,  C07C59/90 ,  C07C323/22 ,  C07C2602/08 ,  C07D263/32

Abstract: Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.

Abstract translation: 式（I）化合物：其中A，R 1，R 2，X，Y和Z在说明书中定义，其制备方法 化合物，其用于治疗血脂异常，动脉粥样硬化和糖尿病的用途，以及包含它们的药物组合物。

公开(公告)号：US20070254919A1

公开(公告)日：2007-11-01

申请号：US11629176

申请日：2005-05-19

Applicant: Philippe Guedat ,  Francois Collonges ,  Olivier Chevreuil ,  Herve Dumas ,  Marie Denault ,  Stephane Yvon ,  Peter Kane ,  Julia Lainton ,  Avril Robertson ,  Bernd Wendt

Inventor： Philippe Guedat ,  Francois Collonges ,  Olivier Chevreuil ,  Herve Dumas ,  Marie Denault ,  Stephane Yvon ,  Peter Kane ,  Julia Lainton ,  Avril Robertson ,  Bernd Wendt

IPC: A61K31/445 ,  A61P3/10 ,  C07D211/06

CPC classification number: C07D211/46 ,  C07D211/96 ,  C07D213/12 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12

Abstract: The present invention relates to derivatives of aroyl-O-piperidine structure of the general formula (I): in which R1, R2, R3 and R4 are as defined in the description. Application of the compounds of the formula (I) to the treatment of hyper-triglyceridaemia, hypercholesterolaemia and dyslipidaemia, and to the prevention or treatment of obesity.

Abstract translation: 本发明涉及通式（I）的芳酰基-O-哌啶结构的衍生物：其中R 1，R 2，R 3， SUP>和R 4'如说明书中所定义。 式（I）化合物用于治疗高甘油三酯血症，高胆固醇血症和血脂异常，以及预防或治疗肥胖症的应用。